Guadecitabine: Phase I/II started

Cancer Research UK began the double-blind, placebo-controlled, U.K. Phase I/II SPIRE trial to evaluate subcutaneous guadecitabine from Otsuka’s Astex Pharmaceuticals Inc. subsidiary plus cisplatin a...